Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 796 across all filing types
Latest filing 2025-03-04 Board/Management Inform…
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Board/Management Information Classification · 1% confidence The document explicitly reports on the results of the '2025 Extraordinary General Meeting of Shareholders (EGM)'. It details the adoption of proposals, specifically the appointment of a new CEO and approval of remuneration. This content directly relates to shareholder meetings and the outcomes thereof. The closest matching category is 'AGM Information' (AGM-R), which covers presentations and materials shared during the Annual General Meeting, and by extension, Extraordinary General Meetings (EGM) concerning governance and voting outcomes. Although it mentions voting results, the primary focus is the meeting's outcome and management changes resulting from it, making AGM-R the most appropriate fit over DVA (which is strictly the declaration of voting results). The document is a press release announcing the meeting's conclusion, not the formal voting result declaration itself.
2025-03-04 English
6-K
Foreign Filer Report
2025-03-04 English
Pharming Technologies B.V. vergroot haar belang in Abliva AB (publ) naar 92,70 procent
M&A Activity Classification · 1% confidence The document is a press release detailing the increased shareholding percentage (92.70%) of Pharming Technologies B.V. in Abliva AB (publ) following a recommended cash offer (the 'Bod'). It discusses the extension of the acceptance period, the intention to start a compulsory buy-out procedure, and delisting plans. This content directly relates to a takeover bid or merger activity, specifically the final stages of a tender offer. This aligns perfectly with the definition for M&A Activity (TAR). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K) as it focuses on the transaction mechanics rather than periodic financial performance. It is not a Report Publication Announcement (RPA) because it contains substantive details about the transaction outcome, not just an announcement that a report is available.
2025-02-21 Dutch
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
M&A Activity Classification · 1% confidence The document is a press release detailing the increased ownership stake of Pharming Technologies B.V. in Abliva AB (publ) following a recommended cash offer (tender offer). It explicitly mentions the offer, the acceptance percentages, the extension of the acceptance period, and the intention to initiate a compulsory acquisition procedure followed by a delisting of Abliva shares from Nasdaq Stockholm. This entire process—a tender offer leading to majority control and subsequent delisting—falls under the category of Merger & Acquisition (M&A) activity or a takeover bid. The closest matching category is 'M&A Activity' (TAR), which covers merger proposals or takeover bids. While it mentions delisting (DLST), the primary subject is the successful tender offer/takeover.
2025-02-21 English
6-K
Foreign Filer Report
2025-02-20 English
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
M&A Activity Classification · 1% confidence The document is a press release from Pharming Technologies B.V. announcing that it has declared its recommended cash offer (Bod) for Abliva AB unconditional, completed the offer based on the acceptance level achieved (87.7%), and extended the acceptance period for remaining shareholders. The text explicitly discusses an 'aanbevolen bod in contanten' (recommended cash offer), the publication of an 'aanbiedingsdocument' (offer document), acceptance levels, and the intention to initiate compulsory acquisition proceedings ('verplichte overnameprocedure') to delist the shares. This content directly relates to a takeover bid or merger proposal, which aligns with the definition for M&A Activity (TAR). Although it is a press release announcing the status of the offer, the core subject matter is the transaction itself, making TAR more specific than a general RPA or RNS.
2025-02-10 Dutch

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.